Non-small cell lung cancer, NRG1-positive

Page editor		Section editor
	Eric K. Singhi, MD MD Anderson Cancer Center Houston, TX, USA LinkedIn		Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN, USA LinkedIn

Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
There are several related dedicated pages:

• Histology-specific:
  • NSCLC, Nonsquamous
  • NSCLC, Squamous
• Site-specific:
  • NSCLC, CNS metastases

Last updated on 2024-12-22: 1 regimens on this page 1 variants on this page

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ASCO

• 2022: Singh et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline PubMed

ESMO

• 2024: Lee et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer PubMed
• 2023: Hendriks et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PubMed

NCCN

• NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Non-Small Cell Lung Cancer.

Advanced or metastatic disease, subsequent lines of therapy

Zenocutuzumab monotherapy

Regimen

FDA-recommended dose

Study	Dates of enrollment	Evidence
Awaiting publication (eNRGy)	Not reported	Phase 1/2 (RT)

Biomarker eligibility criteria

• NRG1 fusion positive

Targeted therapy

• Zenocutuzumab (Bizengri) 750 mg IV once on day 1

14-day cycles

References

1. eNRGy: NCT02912949